Cerity Partners LLC Boosts Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Cerity Partners LLC raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 296,759 shares of the medical research company’s stock after purchasing an additional 10,496 shares during the period. Cerity Partners LLC’s holdings in IQVIA were worth $70,323,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc increased its position in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA in the 2nd quarter worth approximately $27,000. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the 3rd quarter worth approximately $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA in the 3rd quarter worth approximately $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA in the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQV opened at $201.82 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The firm has a fifty day moving average price of $222.67 and a 200 day moving average price of $227.16. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The stock has a market cap of $36.63 billion, a P/E ratio of 26.49, a P/E/G ratio of 2.03 and a beta of 1.51.

Analyst Ratings Changes

A number of research analysts have recently issued reports on IQV shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Friday, November 1st. BTIG Research cut their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Morgan Stanley dropped their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.